The Efficacy and Safety of First-Line Single-Inhaler Triple versus Dual Therapy in Controller-Naïve and Symptomatic Adults with Asthma: A Preliminary Retrospective Cohort Study

References

• Global Initiative for Asthma. The global strategy for asthma management and prevention; 2021. Available from: https://ginasthma.org/. Accessed March 9, 2022.
   Google Scholar
• Kim LHY, Saleh C, Whalen-Browne A, O’Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325(24):2466–2479. doi:10.1001/jama.2021.7872
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, Phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Hozawa S, Sagara H, et al. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Curr Med Res Opin. 2021;37(9):1657–1665. doi:10.1080/03007995.2021.1944849
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9
   PubMed Web of Science ®Google Scholar
• Sagara H, Barbier N, Ishii T, et al. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population. BMJ Open Respir Res. 2021;8(1):e000856. doi:10.1136/bmjresp-2020-000856
   PubMed Web of Science ®Google Scholar
• Padrão E, Araújo D, Todo Bom A, et al. Asthma-COPD overlap: a Portuguese survey. Pulmonology. 2018:S2173–5115. doi:10.1016/j.rppnen.2017.11.009
   PubMed Web of Science ®Google Scholar
• Park SY, Kim S, Kim JH, et al. A randomized, noninferiority trial comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD overlap (ACO) treatment: the ACO Treatment With Optimal Medications (ATOMIC) study. J Allergy Clin Immunol Pract. 2021;9(3):1304–1311. doi:10.1016/j.jaip.2020.09.066
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Ohkura N, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate improves inspiratory capacity in patients with asthma-chronic obstructive pulmonary disease overlap. Int J Chron Obstruct Pulmon Dis. 2020;15:269–277. doi:10.2147/COPD.S231004
   PubMed Web of Science ®Google Scholar
• Yanagisawa S, Ichinose M. Definition and diagnosis of asthma-COPD overlap (ACO). Allergol Int. 2018;67(2):172–178. doi:10.1016/j.alit.2018.01.002
   PubMed Web of Science ®Google Scholar
• Bassam M, Behbehani N, Farouk H, et al. Adherence to medication among adult asthma patients in the Middle East and North Africa: results from the ESMAA study. Respir Med. 2021;176:106244. doi:10.1016/j.rmed.2020.106244
   PubMed Web of Science ®Google Scholar
• Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 asthma insight and management survey. Allergy Asthma Proc. 2012;33(1):54–64. doi:10.2500/aap.2011.32.3518
   PubMed Web of Science ®Google Scholar
• Braido F, Brusselle G, Guastalla D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res. 2016;17(1):51. doi:10.1186/s12931-016-0374-z
   PubMed Web of Science ®Google Scholar
• Adachi M, Hozawa S, Nishikawa M, Yoshida A, Jinnai T, Tamura G. Asthma control and quality of life in a real-life setting: a cross-sectional study of adult asthma patients in Japan (ACQUIRE-2). J Asthma. 2019;56(9):1016–1025. doi:10.1080/02770903.2018.1514628
   PubMed Web of Science ®Google Scholar
• Reddel HK, Vestbo J, Agustí A, et al. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. Eur Respir J. 2021;58(3):2003927. doi:10.1183/13993003.03927-2020
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–556. doi:10.1016/j.jaci.2006.01.011
   PubMed Web of Science ®Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008
   PubMed Web of Science ®Google Scholar
• Jia CE, Zhang HP, Lv Y, et al. The asthma control test and asthma control questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131(3):695–703. doi:10.1016/j.jaci.2012.08.023
   PubMed Web of Science ®Google Scholar
• Szentes BL, Schultz K, Nowak D, Schuler M, Schwarzkopf L. How does the EQ-5D-5L perform in asthma patients compared with an asthma-specific quality of life questionnaire. BMC Pulm Med. 2020;20(1):168. doi:10.1186/s12890-020-01205-8
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Hamada K, Oishi K, Yano M, Yamaji Y, Hirano T. Factors associated with physician-patient discordance in the perception of asthma control. J Allergy Clin Immunol Pract. 2019;7(8):2634–2641. doi:10.1016/j.jaip.2019.04.046
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Schiavetti I, Sorbello V, Ricciardolo FL. Perception of asthma symptoms as assessed on the visual analog scale in subjects with asthma: a real-life study. Respir Care. 2016;61(1):23–29. doi:10.4187/respcare.04171
   PubMed Web of Science ®Google Scholar
• Ohta K, Jean Bousquet P, Akiyama K, et al. Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan. J Asthma. 2013;50(5):514–521. doi:10.3109/02770903.2013.786726
   PubMed Web of Science ®Google Scholar
• Flood EM, De Cock E, Mörk AC, Revicki DA. Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries. Health Qual Life Outcomes. 2006;4:51. doi:10.1186/1477-7525-4-51
   PubMed Web of Science ®Google Scholar
• Laforest L, El Hasnaoui A, Pribil C, Ritleng C, Schwalm MS, Van Ganse E. Asthma patients’ perception of their ability to influence disease control and management. Ann Allergy Asthma Immunol. 2009;102(5):378–384. doi:10.1016/S1081-1206(10)60508-X
   PubMed Web of Science ®Google Scholar
• Laforest L, El Hasnaoui A, Pribil C, et al. Asthma patients’ self-reported behaviours toward inhaled corticosteroids. Respir Med. 2009;103(9):1366–1375. doi:10.1016/j.rmed.2009.03.010
   PubMed Web of Science ®Google Scholar
• Fujiki R, Kawayama T, Furukawa K, Kinoshita T, Matsunaga K, Hoshino T. Daytime and nighttime visual analog scales may be useful in assessing asthma control levels before and after treatment. J Asthma Allergy. 2022;15:1549–1559. doi:10.2147/JAA.S381985
   PubMed Web of Science ®Google Scholar
• Bourdin A, Fabry-Vendrand C, Ostinelli J, et al. The burden of severe asthma in France: a case-control study using a medical claims database. J Allergy Clin Immunol Pract. 2019;7(5):1477–1487. doi:10.1016/j.jaip.2018.12.029
   PubMed Web of Science ®Google Scholar
• Omachi TA, Iribarren C, Sarkar U, et al. Risk factors for death in adults with severe asthma. Ann Allergy Asthma Immunol. 2008;101(2):130–136. doi:10.1016/S1081-1206(10)60200-1
   PubMed Web of Science ®Google Scholar
• Seale JP, Jenkins C, Wood-Baker R, et al. Benefits of fixed-dose combination therapy with inhaled corticosteroids and long-acting bronchodilators as initial maintenance therapy in the management of asthma. Respirology. 2009;14(2):224–229. doi:10.1111/j.1440-1843.2008.01440.x
   PubMed Web of Science ®Google Scholar
• Parimi M, Svedsater H, Ann Q, et al. Persistence and adherence to ICS/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916–2931. doi:10.1007/s12325-020-01344-8
   PubMed Web of Science ®Google Scholar
• Buhl R, Heaney LG, Loefroth E, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020;162:105859. doi:10.1016/j.rmed.2019.105859
   PubMed Web of Science ®Google Scholar
• Lin J, Fu X, Jiang P, et al. INITIAL - An observational study of disease severity in newly diagnosed asthma patients and initial response following 12 weeks’ treatment. Sci Rep. 2019;9(1):1254. doi:10.1038/s41598-018-36611-w
   PubMedGoogle Scholar
• Hasegawa T, Koya T, Sakagami T, et al. The Asthma Control Test, Japanese version (ACT-J) as a predictor of Global Initiative for Asthma (GINA) guideline-defined asthma control: analysis of a questionnaire-based survey. Allergol Int. 2013;62(3):323–330. doi:10.2332/allergolint.13-OA-0535
   Web of Science ®Google Scholar
• Exhaled NO. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig. 2014;52(4):242–250. doi:10.1016/j.resinv.2014.03.003
   PubMedGoogle Scholar
• Soriano JB, Miravitlles M, García-Río F, et al. Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. Prim Care Respir J. 2012;21(2):187–193. doi:10.4104/pcrj.2012.00027
   PubMedGoogle Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380. doi:10.1111/bcp.12637
   PubMed Web of Science ®Google Scholar
• Arif AA, Rohrer JE, Delclos GL. A population-based study of asthma, quality of life, and occupation among elderly Hispanic and non-Hispanic whites: a cross-sectional investigation. BMC Public Health. 2005;5:1. doi:10.1186/1471-2458-5-97
   PubMed Web of Science ®Google Scholar
• Luyster FS, Teodorescu M, Bleecker E, et al. Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath. 2012;16(4):1129–1137. doi:10.1007/s11325-011-0616-8
   PubMed Web of Science ®Google Scholar
• Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1083 adults with asthma from the UK. Prim Care Respir J. 2013;22(4):431–438. doi:10.4104/pcrj.2013.00091
   PubMedGoogle Scholar
• Maspero JF, Jardim JR, Aranda A, et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J. 2013;6(1):19. doi:10.1186/1939-4551-6-19
   PubMedGoogle Scholar
• Svedsater H, Roberts J, Patel C, Macey J, Hilton E, Bradshaw L. Life impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groups. Adv Ther. 2017;34(6):1466–1481. doi:10.1007/s12325-017-0557-0
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa1208606
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Zappa MC, et al. The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. Eur Respir Rev. 2022;31(164):210196. doi:10.1183/16000617.0196-2021
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11(3):239–253. doi:10.1080/17476348.2017.1289844
   PubMed Web of Science ®Google Scholar